Landlocked developing countries (LLDCs) vs Peru: Proportion of the target population who received the final dose of
Landlocked developing countries (LLDCs)
44.0%
in 2024
Peru
97.0%
in 2024
Landlocked developing countries (LLDCs) rank
5th
Peru rank
3rd
Proportion of the target population who received the final dose of over time
- Landlocked developing countries (LLDCs)
- Peru
How they compare
Peru currently reports 97.0% against 44.0% in Landlocked developing countries (LLDCs), a difference of 53.0%.
That makes Peru's figure about 2.2 times Landlocked developing countries (LLDCs)'s.
The two have swapped places 4 times across 14 shared years of data; in 2011 it was Peru ahead.
Landlocked developing countries (LLDCs) ranks 5th and Peru ranks 3rd of 13 regions.
Peru has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Landlocked developing countries (LLDCs) | Peru | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5.9% | 40.4% | 34.6% | Peru |
| 2020s | 28.2% | 53.2% | 25.0% | Peru |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received the final dose of, Landlocked developing countries (LLDCs) or Peru?
- Peru, at 97.0% against 44.0% in Landlocked developing countries (LLDCs) as of 2024.
- What is the difference in proportion of the target population who received the final dose of between Landlocked developing countries (LLDCs) and Peru?
- 53.0%, with Peru ahead.
- How many years of comparable data are there for Landlocked developing countries (LLDCs) and Peru?
- 14 years are reported by both, from 2011 to 2024.
- How do Landlocked developing countries (LLDCs) and Peru rank globally for proportion of the target population who received the final dose of?
- Landlocked developing countries (LLDCs) ranks 5th and Peru ranks 3rd of 13 regions.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received the final dose of human papillomavirus (HPV) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.